Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00211471 · ClinicalTrials.gov registry record · Phase 2
Treatment of Rubeosis Iridis With Open-Label Anecortave Acetate Sterile Suspension ( 15 mg.).
A Phase 2 study, sponsored by Manhattan Eye, Ear & Throat Hospital.
- Terminated
- Registry status
- Phase 2
- Development phase
NCT00211471: Clinical Trial Phase 2 study, sponsored by Manhattan Eye, Ear & Throat Hospital.
NCT00211471 is a Phase 2 study that was terminated before completion, run by Manhattan Eye, Ear & Throat Hospital. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00211471, a Phase 2 study, was terminated before completion, sponsored by Manhattan Eye, Ear & Throat Hospital.
- TERMINATED
- Registry status
- Phase 2
- Development phase
Study Summary
To provide use of Anecortave Acetate Sterile Suspension of 15mg for a series of five patients with rubeosis iridis. Rubeosis iridis refers to neovascularization of the iris. It is caused by a number of conditions which include, but are not limited to severe diabetic retinopathy, central retinal vein occlusion, chronic inflammation, and infection. Anecortave acetate is an angiostatic, experimental drug that is being tested to prevent the growth of blood vessels under the retina in patients with age-related macular degeneration (AMD). Therefore, it is logical to apply the usage of Anecortave to patient's with rubeosis iridis in order to reduce the neovascularization stimulus and cause the regression of the abnormal iris vessels.
Interventions
- DRUG anecortave acetate
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-03 |
| Est. Completion | 2007-05 |
| Phase | Phase 2 |
Why NCT00211471 stopped before completion
NCT00211471 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which anecortave acetate is the first listed.
NCT00211471 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00211471 about?
NCT00211471 is a clinical study titled "Treatment of Rubeosis Iridis With Open-Label Anecortave Acetate Sterile Suspension ( 15 mg.).". To provide use of Anecortave Acetate Sterile Suspension of 15mg for a series of five patients with rubeosis iridis. Rubeosis iridis refers to neovascularization of the iris. It is caused by a number of conditions which include, but are not limited to severe diabetic retinopathy, central retinal vein...
What is the current status of trial NCT00211471?
This trial is currently terminated. It is a Phase 2 study. The study started on 2002-03. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00211471?
The interventions under investigation include: anecortave acetate (DRUG).
Who is sponsoring clinical trial NCT00211471?
This trial is sponsored by Manhattan Eye, Ear & Throat Hospital, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia